8a4t

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (07:00, 21 November 2024) (edit) (undo)
 
(One intermediate revision not shown.)
Line 12: Line 12:
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
-
SARS-CoV-2 is the causative agent behind the COVID-19 pandemic. The main protease (M(pro), 3CL(pro)) of SARS-CoV-2 is a key enzyme that processes polyproteins translated from the viral RNA. M(pro) is therefore an attractive target for the design of inhibitors that block viral replication. We report the diastereomeric resolution of the previously designed SARS-CoV-2 M(pro) alpha-ketoamide inhibitor 13b. The pure (S,S,S)-diastereomer, 13b-K, displays an IC50 of 120 nM against the M(pro) and EC50 values of 0.8-3.4 muM for antiviral activity in different cell types. Crystal structures have been elucidated for the M(pro) complexes with each of the major diastereomers, the active (S,S,S)-13b (13b-K), and the nearly inactive (R,S,S)-13b (13b-H); results for the latter reveal a novel binding mode. Pharmacokinetic studies show good levels of 13b-K after inhalative as well as after peroral administration. The active inhibitor (13b-K) is a promising candidate for further development as an antiviral treatment for COVID-19.
+
SARS-CoV-2 is the causative agent behind the COVID-19 pandemic. The main protease (M(pro), 3CL(pro)) of SARS-CoV-2 is a key enzyme that processes polyproteins translated from the viral RNA. M(pro) is therefore an attractive target for the design of inhibitors that block viral replication. We report the diastereomeric resolution of the previously designed SARS-CoV-2 M(pro) alpha-ketoamide inhibitor 13b. The pure (S,S,S)-diastereomer, 13b-K, displays an IC(50) of 120 nM against the M(pro) and EC(50) values of 0.8-3.4 muM for antiviral activity in different cell types. Crystal structures have been elucidated for the M(pro) complexes with each of the major diastereomers, the active (S,S,S)-13b (13b-K), and the nearly inactive (R,S,S)-13b (13b-H); results for the latter reveal a novel binding mode. Pharmacokinetic studies show good levels of 13b-K after inhalative as well as after peroral administration. The active inhibitor (13b-K) is a promising candidate for further development as an antiviral treatment for COVID-19.
-
Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease.,Cooper MS, Zhang L, Ibrahim M, Zhang K, Sun X, Roske J, Gohl M, Bronstrup M, Cowell JK, Sauerhering L, Becker S, Vangeel L, Jochmans D, Neyts J, Rox K, Marsh GP, Maple HJ, Hilgenfeld R J Med Chem. 2022 Oct 13;65(19):13328-13342. doi: 10.1021/acs.jmedchem.2c01131., Epub 2022 Sep 30. PMID:36179320<ref>PMID:36179320</ref>
+
Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease.,Cooper MS, Zhang L, Ibrahim M, Zhang K, Sun X, Roske J, Gohl M, Bronstrup M, Cowell JK, Sauerhering L, Becker S, Vangeel L, Jochmans D, Neyts J, Rox K, Marsh GP, Maple HJ, Hilgenfeld R J Med Chem. 2022 Oct 13;65(19):13328-13342. doi: 10.1021/acs.jmedchem.2c01131. , Epub 2022 Sep 30. PMID:36179320<ref>PMID:36179320</ref>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>

Current revision

crystal structures of diastereomer (S,S,S)-13b (13b-K) in complex with the SARS-CoV-2 Mpro

PDB ID 8a4t

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools